Please login to the form below

Emotion-driven clinical trial marketing: A missed opportunity?

Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert Simon, a American Nobel Laureate scientist, speak extensively about how emotions can influence, skew and determine the outcome of so many decisions we’re confronted with every day.

Before we dive in to this article, we need to understand how the emotions that effect decision-making are formed and how they’re transformed into actionable feelings. So, let’s have a quick look into the science behind the idea…

The science behind emotion

All feelings first start with an external stimulus. This could be a physical or verbal interaction. Whatever the event is, it generates an unfelt emotion in the brain, which causes the body to produce responsive chemicals. Following this, a cascade of events leads to changes to our mood and feelings. These emotions can impact any decisions we make and how quickly we make them. Further, emotional information automatically triggers adaptive behavioural modules that we’ve evolved, pushing us to lean towards appealing outcomes and avoid anything we find threatening.

Despite this knowledge and understanding, we shy away from using these insights to direct the clinical study advertising we create. According to CISCRP surveys, patients cite advancing science and improving the lives of others as main drivers for participating in research. And we so often talk about altruism being an important factor in people wanting to join a clinical study, which is a particularly emotional trigger. However, just as often, the creative we develop to inspire action lacks that very emotion. With recent research highlighting potential opportunity for clinical study patient recruitment advertising to take a more emotive approach, our interest is certainly piqued.

Keeping guidelines in mind

Of course, it goes without saying that any clinical study advertising and marketing must still adhere to ethics guidelines. And with the emotion being both abstract and subjective, it’s important that messaging or imagery aren’t seen to be coercive or suggestive of safe and effective treatments or outcomes. But that doesn’t mean that a more emotive angle can’t be considered. And here’s the findings to back the theory…

Fear and hope prove to trigger action

A study by Wunderman Health found that emotional triggers, in particular fear and hope, inspire action. With decades of failed anti-smoking campaigns and an abundance of information and marketing, the study looked at why people continued to light up and also highlighted opportunity to try a new approach.

The marketing campaigns that were put under the microscope centred around three different types of motivations:

  1. Having a good life
  2. Achieving family security
  3. Making social connections

And the emotions looked into were:

  • Fear
  • Joy
  • Hope

The findings of the study included:

A desire for a good life + fear = shocked into action

When people motivated by a desire to have a good life were exposed to content that triggered their fears, they felt nearly three times more surprise (+269%).

A desire for a good life + hope = deeper concentration and reflection

When people motivated by a desire to have a good life were exposed to content that triggered hope, their concentration increased by 46% and they ‘reflected more deeply’ about their reasons and plans for quitting.

A desire for family security = planning for action

When people motivated by a desire to achieve family security were exposed to content targeting that desire, they were 16% more likely to create a plan to quit smoking.

Becky Chidester, CEO of Wunderman Health, gave her thoughts on the study, saying:

People act on motivation, not information, and on content that stirs both negative and positive emotions over a period of time. The healthcare industry has done a great job educating people about medical conditions and treatments, but it has missed the mark in creating content that truly stimulates action.

More details on the study, including the marketing content that was put into testing, can be found here.

Uncovering motivators that matter

Looking at the study’s findings, it’s clear that understanding people’s specific motivators to participate in a clinical study is a priority for any clinical study. There are numerous ways in which you can glean these important insights, and digital interactions make doing so easier than ever before. For an example and further guidance, just take a look at another of our blogs where we explore how social listening can be an incredible untapped resource for clinical studies.

Through this understanding, you’re able to bring genuine empathy into your campaigns. Research professor Brené Brown describes empathy as “feeling with people”, which can help keep a human and patient-focussed approach within everything you create. It stops you talking about how great the clinical study is, and instead start talking about patients’ needs, showing that you understand them.

Yannis Kotziagkiaouridis, Global Chief Analytics Officer of Wunderman, said:

By drilling down into why people make the choices they do, and by crafting marketing content that speaks to their hearts as well as their minds, we now have the ability to spur both small and very large groups of people to action.

And we couldn’t have said it better ourselves.

We have plenty of our own expert insight and guidance on how the industry can improve how we connect with patients, and the strength of those connections, in our patient engagement white paper. Check it out here.

This blog was first published here:

14th August 2020



Company Details

COUCH Health

+44 (0) 330 995 0656

Contact Website

Suite 2.10, Jactin House
24 Hood Street
M4 6WX
United Kingdom

Latest content on this profile

3 reasons why clinical trials will thrive in 2021
It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical trials since the first case of COVID-19 in early 2020. With reduced access to primary care, limited capacity in hospitals, and clinical trial participants unable to visit investigator sites, it’s taken countless innovative changes in procedures to enable hospitals, clinics, and clinical trials to continue to serve patients throughout the pandemic.
COUCH Health
#DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much more, many groups remain underrepresented, including the elderly, certain ethnic groups and the LGTBQ+ community.
COUCH Health
New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021.
COUCH Health
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs.
COUCH Health
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial is about and to ensure consent is informed. And be something that people are going to remember. And with some trials lasting years, building awareness and familiarity is key to improve engagement. That’s where your clinical trial branding comes in…
COUCH Health
October 2020: diversity and inclusion in clinical trials round-up
In our latest round-up of news surrounding diversity and inclusion in clinical trials, we take a closer look into the benefits that diversity can bring to society, learnings that we can take from the COVID-19 pandemic to shift our thinking around diversity and clinical trials, how we can address long-standing barriers to build trust in healthcare, and much more.
COUCH Health